Navigation Links
Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
Date:5/19/2008

ated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with internal development and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under t
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
2. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
3. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
4. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
5. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
10. Neurocrine Biosciences Reports First Quarter 2008 Results
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Tobago , July 25, 2014  The ... & Tobago Ministry of Health approved the introduction ... significantly increases the cure rate from Hepatitis C, ... the genotype 1 virus. Telaprevir is available in ... brand INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg ...
(Date:7/25/2014)... According to a new market ... Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and ... and Forecast (Value and Volume), 2013 - 2019", the ... in 2012 and is expected to grow at a ... USD 32.24 billion in 2019. Browse the ...
(Date:7/25/2014)... 2014  AMETEK, Inc. (NYSE: AME ) ... as Vice President and General Manager, Engineered Medical ... Division. "I am pleased that Kurt has ... development experience, especially in the medical device industry, and ... continued growth and success of our medical components businesses," ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... 17, 2011 Reportlinker.com announces that a ... its catalogue: Depression Therapeutics ... 2018 http://www.reportlinker.com/p0656880/Depression-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Market Forecasts to 2018 ...
... Par Pharmaceutical, Inc., the wholly-owned subsidiary of Par ... announced that it filed a declaratory judgment complaint and ... in Washington, D.C. seeking to preserve Par,s First Amendment ... healthcare providers about the FDA-approved, on-label use of Par,s ...
Cached Medicine Technology:Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 2Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 3Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 4Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 5Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 6Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 7Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 8Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 9Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 10Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 2Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 3Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 4
(Date:7/28/2014)... TherapySites, the leading website and ... its affiliation with the Illinois Association for Marriage ... TherapySites to continue to extend their online marketing solutions ... , “There has been a fundamental shift in the ... 3 billion Internet users, it is so important to ...
(Date:7/28/2014)... Wa (PRWEB) July 28, 2014 According to ... this is a comprehensive guide that will help people get ... to readers all the necessary information about heartburn and acid ... the truth about heartburn , and risk factors for reflux ... book will help people get rid of symptoms of reflux ...
(Date:7/28/2014)... Shore Points Capital announced today that ... Loftware, Inc., through a recapitalization of the Company led ... lead investor in Loftware for over nine years, a ... international provider of enterprise level software solutions for supply ... investment for us, and we are proud of everything ...
(Date:7/27/2014)... 2014 Hyaluronic Acid can hold 1,000 ... key to the power of Hyaluronic Serums. , "Hyaluronic ... founder of Sublime Beauty®. "But like collagen, it diminishes ... ours improves skin moisture-retention and radiance." , Hyaluronic ... a healthy and beautiful look. Key Ingredients in the ...
(Date:7/27/2014)... The first systematic analysis of hepatitis E virus (HEV) ... 3000 donors in England have HEV in their plasma. ... that around 1200 HEV-containing blood components (eg, red cells, ... transfused every year in England. , The study ... south east England between Oct, 2012 and Sept, 2013 ...
Breaking Medicine News(10 mins):Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
... ... speaker, from standing on top of the world and sharing her story of hope and determination. ... Bayfield, WI (PRWEB) April 7, 2010 ... for this year,s attempt to climb the world,s highest peak. Last year,s successful climbers whose ...
... ... to Win an Appearance on National Television—or Win an Apple iPad™ in the “Best Seller ... ... lead to TODAY’S publishing of Gerry Czarnecki’s latest book… Lead with Love. This is ...
... An analysis by Mount Sinai researchers of over eight years ... that the relationship between high consumption of fruits and vegetables ... as commonly thought. The study is published online April 6, ... . It is widely believed that a diet rich ...
... Those with abnormalities at initial screening often didn,t have ... News) -- Black Americans are less likely than whites ... on a flexible sigmoidoscopy screening test, says a new ... be at greater risk for colorectal cancer and more ...
... , TUESDAY, April 6 (HealthDay News) -- The use of ... the past six years, even though these operations are ... more effective, a study finds. , "It was a bit ... said Dr. Richard A. Deyo, professor of family medicine and ...
... An approach designed to reduce HIV/STDs previously used ... community-based organizations (CBOs), an important component in national strategies ... "at risk" youths can be reached. , A ... tested whether a proven HIV/STD risk-reduction intervention would work ...
Cached Medicine News:Health News:Woman with MS Summits Everest and Completes the Seven Summits 2Health News:Woman with MS Summits Everest and Completes the Seven Summits 3Health News:‘Leading' the Bestseller Race: Today We Publish —Tomorrow We Prevail! 2Health News:‘Leading' the Bestseller Race: Today We Publish —Tomorrow We Prevail! 3Health News:Mount Sinai study finds only a weak link between fruit and vegetable and reduced risk of cancer 2Health News:Blacks Less Likely to Get Follow-Up Colon Screening 2Health News:Complex Spinal Operations Soar Despite Drawbacks 2Health News:Complex Spinal Operations Soar Despite Drawbacks 3Health News:Roll-out of proven HIV/STD risk-reduction intervention with teens by community groups successful 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: